ObjectiveTo determine the clinical manifestations, risk factors, and maternal and perinatal outcomes in pregnant and recently pregnant women with suspected or confirmed coronavirus disease 2019 (covid-19). DesignLiving systematic review and meta-analysis. Data sOurcesMedline, Embase, Cochrane database, WHO COVID-19 database, China National Knowledge Infrastructure (CNKI), and Wanfang databases from 1 December 2019 to 26 June 2020, along with preprint servers, social media, and reference lists. stuDy selectiOnCohort studies reporting the rates, clinical manifestations (symptoms, laboratory and radiological findings), risk factors, and maternal and perinatal outcomes in pregnant and recently pregnant women with suspected or confirmed covid-19. Data extractiOnAt least two researchers independently extracted the data and assessed study quality. Random effects meta-analysis was performed, with estimates pooled as odds ratios and proportions with 95% confidence intervals. All analyses will be updated regularly. results 77 studies were included. Overall, 10% (95% confidence interval 7% to14%; 28 studies, 11 432 women) of pregnant and recently pregnant women attending or admitted to hospital for any reason were diagnosed as having suspected or confirmed covid-19. The most common clinical manifestations of covid-19 in pregnancy were fever (40%) and cough (39%). Compared with non-pregnant women of reproductive age, pregnant and recently pregnant women with covid-19 were less likely to report symptoms of fever (odds ratio 0.43, 95% confidence interval 0.22 to 0.85; I 2 =74%; 5 studies; 80 521 women) and myalgia (0.48, 0.45 to 0.51; I 2 =0%; 3 studies; 80 409 women) and were more likely to need admission to an intensive care unit (1.62, 1.33 to 1.96; I 2 =0%) and invasive ventilation (1.88, 1.36 to 2.60; I 2 =0%; 4 studies, 91 606 women). 73 pregnant women (0.1%, 26 studies, 11 580 women) with confirmed covid-19 died from any cause. Increased maternal age (1.78, 1.25 to 2.55; I 2 =9%; 4 studies; 1058 women), high body mass index (2.38, 1.67 to 3.39; I 2 =0%; 3 studies; 877 women), chronic hypertension (2.0, 1.14 to 3.48; I 2 =0%; 2 studies; 858 women), and pre-existing diabetes (2.51, 1.31 to 4.80; I 2 =12%; 2 studies; 858 women) were associated with severe covid-19 in pregnancy. Pre-existing maternal comorbidity was a risk factor for admission to an intensive care unit (4.21, 1.06 to 16.72; I 2 =0%; 2 studies; 320 women) and invasive ventilation (4.48, 1.40 to 14.37; I 2 =0%; 2 studies; 313 women). Spontaneous preterm birth rate was 6% (95% confidence interval 3% to 9%; I 2 =55%; 10 studies; 870 women) in women with covid-19. The odds of any preterm birth (3.01, 95% confidence interval 1.16 to 7.85; I 2 =1%; 2 studies; 339 women) was high in pregnant women with covid-19 compared with those without the disease. A quarter of all neonates born to mothers with covid-19 were admitted to the neonatal unit (25%) and were at increased risk of admission (odds ratio 3.13, 95% confidence interval 2.05 to 4.78, I 2 =not estimable; 1 st...
Obesity is reaching pandemic proportions worldwide. It is increasingly being recognised as a risk factor during pregnancy. Women should ideally be counselled preconceptionally about the increased risks and encouraged to lose weight actively, some may be candidates for bariatric surgery. Maternal risks include gestational diabetes, hypertension and pre-eclampsia, increased incidence of operative delivery, postpartum haemorrhage, anaesthetic risks as well as infective and thrombo-embolic complications while fetal risks include miscarriage, neural-tube defects, macrosomia and stillbirth. Obstetric units should institute appropriate guidelines for the management of pregnancy in this 'high-risk' group of women.
Headache is a very commonly encountered symptom in pregnancy and is usually due to primary headache disorders which are benign in nature. It can however be quite debilitating for some women who may need therapeutic treatment of which there are several options safe to use in pregnancy. It is equally important though to recognise that headache may be a sign of serious underlying pathology. This paper aims to provide a clinically useful guidance for differentiation between primary and secondary headaches in pregnancy. The primary headache disorders and their management in pregnancy are explored in depth with brief overviews of the causes for secondary headaches and their further investigation and management.
Xu et al. (Eur. Phys. J. C 79 (2019) 708) have anticipated the theory of Gravity. The modified study of [Formula: see text] is elucidated here as Cosmological model. In it the action holds a role as a capricious arbitrary function [Formula: see text]. At this juncture [Formula: see text] functions as non-metricity and for matter fluid, [Formula: see text] outlines as energy-momentum tensor. The function [Formula: see text] quadratic in [Formula: see text] and linear in [Formula: see text] as [Formula: see text] has been taken as our research in which [Formula: see text], [Formula: see text] and [Formula: see text] stand as model parameters, induced by [Formula: see text] gravity. A range of cosmological parameters have been attained by us such as in Universe viz. Hubble parameter [Formula: see text], Friedmann–Lemaitre–Robertson–Walker (FLRW), deceleration parameter [Formula: see text], etc. in terms of scale-factor and in terms of redshift [Formula: see text] by confining to the law of energy-conservation. The fittest values of the model parameters have been acquired by us as the observational constrictions on the model, by utilizing the accessible data sets like Hubble data sets [Formula: see text], union 2.1 compilation of SNe Ia data sets and Joint Light Curve Analysis (JLA) data sets. We have applied [Formula: see text]-test formula. The values of various observational parameters have been premeditated by us viz. [Formula: see text], [Formula: see text], [Formula: see text] and state finder parameters [Formula: see text]. They are absolutely very close to the standard cosmological models. It has also been observed by us that the deceleration parameter [Formula: see text] exhibits signature-flipping (transition) point within the range [Formula: see text]. It is observed that it changes its phase from decelerated to accelerated expanding universe with equation of state (EoS) [Formula: see text] for [Formula: see text].
We have analyzed the Barrow holographic dark energy (BHDE) in the framework of flat FLRW universe by considering the various estimations of Barrow exponent △. Here, we define BHDE, by applying the usual holographic principle at a cosmological system, for utilizing the Barrow entropy rather than the standard Bekenstein–Hawking. To understand the recent accelerated expansion of the universe, consider the Hubble horizon as the IR cutoff. The cosmological parameters, especially the density parameter [Formula: see text], the equation of the state parameter [Formula: see text], energy density [Formula: see text] and the deceleration parameter [Formula: see text] are studied in this paper and found the satisfactory behaviors. Moreover we additionally focus on the two geometric diagnostics, the statefinder [Formula: see text] and [Formula: see text] to discriminant BHDE model from the [Formula: see text]CDM model. Here we determined and plotted the trajectories of evolution for statefinder [Formula: see text], [Formula: see text] and [Formula: see text] diagnostic plane to understand the geometrical behavior of the BHDE model by utilizing Planck 2018 observational information. Finally, we have explored the new Barrow exponent △, which strongly affects the dark energy equation of state that can lead it to lie in the quintessence regime, phantom regime and exhibits the phantom-divide line during the cosmological evolution.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.